The company demonstrated high analytical sensitivity and specificity, and also showed clinical data supporting a high concordance with tumor tissue sequencing.
The researchers found that the noninvasive test could detect signs of transplant rejection and infection in a cohort of 51 patients.
A majority of respondents said liquid biopsy is poised to become a widely used tool for assessing cancer mutations within the next one to four years, with NGS-based analysis preferred over other testing modalities.
TGen researchers used whole-genome bisulfite sequencing of ctDNA to identify 21 hotspots that correlated with disease recurrence in breast cancer patients.
Researchers used bisulfite sequencing to identify methylation markers in order to trace circulating DNA fragments back to their tissue of origin.
The new subsidiary will focus on expanding the company's liquid biopsy technology capabilities and growing European adoption of its platform.
The company also plans to submit its Panorama Microdeletion NIPT for US Food and Drug Administration clearance.
In PNAS this week: tumor DNA in cerebrospinal fluid, genetic factors influencing ability to sweat in humans, and more.
The study paves the way for a clinical trial testing the use of CSF tumor DNA as a biomarker for brain and spinal cord tumors.
The goal is to detect both clonal and subclonal variations and to demonstrate how Natera's technology can help improve cancer patient care and treatment outcomes.
Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.
The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.
Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.
In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.